BioPharma Dive reports that the FDA is still dealing with the aftermath of a significant staff exodus last year, leaving over 1,000 open positions. The agency’s ongoing recruitment challenges are affecting its ability to process pharmaceutical industry requests.
For pharma companies, this means potential delays in drug approvals and regulatory reviews, which could disrupt product launches and market strategies. Senior leaders should expect longer review periods and plan for increased regulatory uncertainty until the agency resolves its staffing issues.
